This study will include 2 groups of participants with subjective cognitive complaints (1) individuals diagnosed with Ehlos Danlos Syndrome (EDS), and older adults without EDS. Participants will complete a 6-week cognitive + occupational therapy tele-rehabilitation program (first 4 weeks: 2 sessions per week, last 2 weeks: 1 session per week), for a total of 10 treatment visits. This study integrates cognitive training with an evidence based OT-led tele-rehabilitation program. We will complete a comprehensive battery of cognitive assessments as well as participant reported outcome measures at the pre and post visits to characterize subjective cognitive difficulties and test the feasibility and initial effect of this personalized intervention.

This study is for patients that have been diagnosed with metastatic or advanced solid tumors. The study is testing an investigational drug called JZP898. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA). The primary purpose of this study is to characterize the safety and tolerability profile of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab. The drug is given to participants by infusion. The length of your participation in this study may vary depending on the number of treatment cycles you receive. This will depend on whether there are any changes in your health during the study and whether the study doctor feels you should continue receiving the study drug.

The purpose of the Re-Spire Study is to help researchers learn more about the efficacy and long-term safety and tolerability of the research drug L606 in participants with PH-ILD.
There are two phases of the Re-Spire Study participants can potentially join with the second phase starting directly after the first phase ends. The first phase is called the "Blinded Treatment Phase" (BTP). This is the "double-blind," assigned by chance portion of the study and will last approximately 28 weeks (a 30-day Screening period followed by a 24-week study period). The second phase of the Re-Spire Study is called the "Open Label Extension Phase" (OLEP). This phase is optional. It is called "open-label" because there is no placebo and everyone who joins will take the active study drug, L606.
About 350 participants will take part in this research study from around 120 study centers or research sites in various countries or regions.

Patients are matched with this clinical trial based on their biomarker test results in the myeloMATCH study. This treatment trial is for adults (ages 18-59) with high-risk AML who have not started treatment yet. Doctors consider AML high risk if it has certain biomarkers that can make it harder to treat. Treatment plans for AML often involve several phases of treatment. The first phase aims to get rid of as many leukemia cells as possible. It helps make it easier for further treatment to keep the cancer under control. Usually, the first treatment patients receive for AML is a combination of 2 chemotherapy drugs, daunorubicin and cytarabine. The purpose of this study is to learn if other options for first treatment may work better for people with high-risk AML. The study doctors will test 4 new treatments and compare them to the usual chemotherapy. This is important because knowing AML is high-risk gives doctors more information about the cancer and how to treat it. People with high-risk AML may benefit from a different approach to treatment. Improving options for people in the first phase of treatment could make further phases of treatment more successful.

The purpose of this research is to assess a stepped care model of a telehealth parenting program for children ages 2-6 years old with a neurodevelopmental diagnosis and behavior problems. Families will complete an online intake assessment, 6 group-based tele-health Parent-Child Interaction Therapy (PCIT) sessions, and an online post intervention assessment. Some families may receive additional individual virtual booster sessions and will complete a second online post assessment.

The BOND study is being done to find new ways to support mothers and their babies after CHD diagnosis. The BOND study has two parts. One part, HeartGPS, will look at how a new emotional support program may help mothers adjust to their baby's diagnosis during pregnancy and after birth. The second part, Direct Breastfeeding will look at how to support mothers who breastfeed. Both parts will look at how these new support programs may improve the well-being of mothers and the bond between mother and baby.

The 18 week study is designed to assess the efficacy and safety of the once daily E2086, in narcolepsy Type 1 and Type 2. Administered upon wakening, 3 different doses will be compared to a placebo. This study requires overnight sleep studies. The effects of E2086 on mean sleep latencies will be examined.

This is a phase 2, randomized, multiple-dose, placebo-controlled, multicenter study to assess the safety, efficacy, and PK of CSL889 IV administration in adults and adolescents with SCD presenting with VOC. All subjects will receive a once daily dose of CSL889 or placebo until VOC resolution or Day 5, whichever comes first.

Youth participation in healthcare is becoming more prevalent, and outcomes are improved when youth have a voice in decisions. Little is known about how much adolescents participate in decision-making about vaccinations including "optional" vaccines or those not required for school attendance. This is a survey to evaluate the extent to which adolescents were involved in the decision to be vaccinated for 4 common vaccines: FLU (influenza), COVID (SARS-CoV-2 virus), MEN (meningococcemia), and HPV (Human Papilloma Virus).

Optic neuritis (ON) is a rare inflammatory disorder of the optic nerve that results in vision loss. It is characterized by rapid and variable vision loss, pain in, around and behind the eye, and changes in color vision. Subjects in this study will be followed for 12 months total and randomized in a 2:1 ratio to receive either an IV infusion medication or a placebo infusion. Low Contrast Visual Acuity will be tracked at 3 months. After 3 months, participants will continue the study
through Month 12 in the safety follow-up part of the study intended to provide longer
term safety information.